Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).
1 finding from 1 review
Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).
1 finding from 1 review
Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in number of participants who died during the study compared with placebo (low certainty).
1 finding from 1 review
Pain (VAS, PRTEE) translated to 0 to 10, where 0 is no pain · lateral elbow pain
1 finding from 1 review
Disability DASH scale. Scale from: 0 to 100. ( · lateral elbow pain
1 finding from 1 review
Treatment success (> 25% improvement in pain or function) · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes treatment success (> 25% improvement in pain or function) compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Health‐related Quality of Life Not measured · lateral elbow pain
1 finding from 1 review
Relief of pain · lateral elbow pain
1 finding from 1 review
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain
Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).
1 finding from 1 review
All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low